

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
11245/46117

Application Number
09/919,408

Filing date
July 31, 2001

Examiner
P. Gambel

Art Unit
1644

Invention Title
**METHOD FOR ISOLATING CELLS AND
EXPRESSING FLK-2 RECEPTORS AND
ISOLATED POPULATIONS OF CELLS THAT
EXPRESS FLK-2 RECEPTORS**


Inventor(s)
Ihor R. LEMISCHKA

Address to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the
United States Postal Service with sufficient postage as first class mail in an
envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450 on: September 15, 2004


By:


Lawrence P. Casson (Reg. No. 46,606)


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 are enclosed.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: September 15, 2004

By:


Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)
CUSTOMER NO. 26646

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 	ATTY. DOCKET NO. 11245/46117	SERIAL NO. 09/919,408
	APPLICANT Ihor R. LEMISCHKA	
	FILING DATE July 31, 2001	GROUP 1644

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5,270,458	December 1993	Lemischka			
	5,283,354	February 1994	Lemischka			
	5,621,090	April 15, 1997	Lemischka et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Bolen et al., FASEB 6, (1992), pp. 3403-3409
	Jones et al., Proc. Nat'l Acad. Sci, USA 85 (1988), pp. 3377-3381
	Matthews et al., PNAS 88:9026-9030, October 1991
	Millauer et al., Cell 72:835-846, 1993
	Nakamura, et al, "Ex Vivo Generation of CD34+ cells from CD34- Hematopoietic cells" Blood, December 15, 1999, Vol. 94, No. 12, pp. 4053-4059
	Nocka et al., "Candidate ligand for the C-kit transmembrane Kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors" Vol. 9, No. 10, pp. 3287-3294, 1990
	Nocka, K. et al., "Expression of C-Kit gene products in known cellular targets of W mutations in normal and W mutant mice-evidence for an impaired C-Kit Kinase in mutant mice, Genes and Development" Vol 3, No. 6, pp. 739-920, 1989
	Peichev, et al., "Expression of VEGFR-3 and AC133 by circulating human CD34 Cells identifies a population of functional endothelial precursors" Blood, February 1, 2000, Vol. 95, No. 3, 953-958
	Sarzani et al., Biochem Biophys Res Comm. 186(2) 706-714 July 31, 1992
	Terman et al., Biochem Biophys Res Comm. 187(3) 1579, 1992
	Wek et al., Proc. Nat'l Acad. Sci, USA 86, (1989), pp. 4579-4583
	Wilks PNAS 86:1603-1607 March 1989
	Yamaguchi, et al., "flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors" Development 118, 489-498, 1993
	Yang et al., J. Neuroscience 16:6089-6099, 1996

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	